Skip to main content

Table 1 Patient characteristics

From: Greater tau load and reduced cortical thickness in APOE ε4-negative Alzheimer’s disease: a cohort study

  APOE ε4-negative
(n = 19)
APOE ε4-positive
(n = 46)
P value
Diagnosis, n (MCI due to AD/AD dementia) 4/15 18/28 0.27
Age (years) 70.1 ± 7.8 72.4 ± 6.8 0.23
Sex, n (male/female) 9/10 18/28 0.29
Education, years 11.1 ± 2.7 12.5 ± 3.4 0.13
APOE genotype ε3/ε3 (n = 19) ε2/ε4 (n = 3)
ε3/ε4 (n = 27)
ε4/ε4 (n = 16)
NA
CSF Aβ42, ng/L 405 ± 97 405 ± 104 0.99
CSF T-tau, ng/L 855 ± 366 673 ± 283 0.035
CSF P-tau, ng/L 105 ± 4 81 ± 31 0.012
WML, mL 15.5 (13.8) 11.9 (14.0) 0.31
Hippocampal volume, mL 2968 (576) 2907 (442) 0.50
MMSE 22.2 ± 5.8 22.6 ± 4.3 0.73
ADAS immediate recall 5.9 ± 1.8 5.9 ± 1.3 0.98
ADAS delayed recall 6.2 ± 3.1 8.0 ± 2.01 0.018
TMT-A 123.6 ± 112.0 75.0 ± 42.5 0.021
AQT-CF 102.9 ± 27.6 91.2 ± 38.5 0.35
Fluency—animals 9.9 ± 6.8 12.1 ± 5.2 0.21
Fluency—letter (S) 8.0 ± 5.6 11.1 ± 4.9 0.055
  1. Continuous data are shown as mean and standard deviations P values are from chi-square tests and linear regression models; significant results (P < 0.05) are indicated in bold. Hippocampal volume was averaged between right and left. Tests for WML and hippocampal volume were adjusted for intracranial volume AD Alzheimer’s disease, ADAS Alzheimer’s disease Assessment Scale, AQT-CF A Quick Test of cognitive speed—color and form, CSF cerebrospinal fluid, MCI mild cognitive impairment, MMSE Mini-Mental State Examination, NA not applicable, TMT-A Trail Making Test-A, WML white matter lesions